GW572016 For Treatment Of Refractory Metastatic Breast Cancer

An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens


Hauptsponsor: GlaxoSmithKline

Quelle GlaxoSmithKline
Kurze Zusammenfassung

This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.

Gesamtstatus Completed
Anfangsdatum November 2003
Fertigstellungstermin February 2005
Primäres Abschlussdatum February 2005
Phase Phase 2
Studientyp Interventional
Primärer Ausgang
Messen Zeitfenster
Tumor response rate
Sekundäres Ergebnis
Messen Zeitfenster
clinical benefit rate time to progression 4 and 6 month progression free survival overall survival
Einschreibung 200

Interventionsart: Drug

Interventionsname: GW572016



Inclusion Criteria:

- Signed Informed Consent.

- Histologically confirmed Stage IIIb or IV breast cancer.

- Refractory breast cancer defined as progression in the metastatic setting after prior therapy with anthracyclines, taxanes and capecitibine.

- Subjects with documented ErbB2 tumor overexpression must have received at least 6 cycles of trastuzumab.

- Documented disease progression of the most recent treatment is required.

- Archived tumor tissue available for testing.

- Measurable lesions according to Response Evaluation Criteria In Solid Tumors (RECIST).

- At least 3 weeks since prior cancer therapies except for trastuzumab which must be discontinued at least 2 weeks prior to the beginning of study drug.

- Bisphosphonate therapy initiated prior to study entry is allowed, however, initiation of bisphosphonates following study entry is not allowed.

- Able to swallow and retain oral medication.

- Cardiac ejection fraction within the institutional normal range as measured by echocardiogram or MUGA (Multiple Gated Acquisition) scan.

- Adequate kidney and liver function.

- Adequate bone marrow function.

Exclusion criteria:

- Pregnant or lactating.

- Copies of nadir scans and/or photographs of the tumor prior to disease progression as well as scans documenting disease progression are not available for review.

- Malabsorption syndrome, ulcerative colitis, disease significantly affecting gastrointestinal function or resection of the stomach or small bowel.

- History of other malignancy.

- Serious medical or psychiatric disorder that would interfere with the patient''s safety or informed consent.

- Active or uncontrolled infection.

- Known history of uncontrolled or symptomatic angina, arrhythmias or congestive heart failure.

- Known history of or clinical evidence of leptomeningeal carcinomatosis.

- Active infection.

- Concurrent cancer therapy or investigational therapy.

- Use of oral or IV steroids.

- Unresolved or unstable serious toxicity from prior therapy.

- Prior treatment with an ErbB1 and/or ERbB2 inhibitor other than trastuzumab.

Geschlecht: Female

Mindestalter: 18 Years

Maximales Alter: N/A

Gesunde Freiwillige: No

Insgesamt offiziell
Nachname Rolle Zugehörigkeit
GSK Clinical Trials Study Director GlaxoSmithKline
GSK Investigational Site | Buenos Aires, C1455BWU, Argentina
GSK Investigational Site | Villejuif Cedex, 94805, France
GSK Investigational Site | Augsburg, Bayern, 86150, Germany
GSK Investigational Site | Sutton, Surrey, SM2 5PT, United Kingdom
GSK Investigational Site | Bebington, Wirral, CH63 4JY, United Kingdom
GSK Investigational Site | London, SW3 6JJ, United Kingdom
GSK Investigational Site | Manchester, M20 4BX, United Kingdom
Standort Länder




United Kingdom


April 2015

Verantwortliche Partei

Art: Sponsor

Bedingung Durchsuchen
Studiendesign Info

Zuweisung: Non-Randomized

Interventionsmodell: Single Group Assignment

Hauptzweck: Treatment

Maskierung: None (Open Label)